Stoke Therapeutics SEC Filings

Stoke Therapeutics, Inc. (STOK) Form 144 notifies the SEC of a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney LLC on 10/03/2025 with an aggregate market value of $248,200.00. The filer reports the shares were acquired the same day on 10/03/2025 by exercise of stock options and paid for in cash. The filing also discloses multiple prior sales by the same person or plan during the past three months, including 15,000+ shares sold across dates in August and September 2025 generating gross proceeds such as $300,491.78 and $205,680.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references reliance on Rule 10b5-1 sales where applicable.

Stoke Therapeutics insider sale executed under a pre-established plan. Chief Medical Officer Barry Ticho sold 5,343 shares of common stock on 10/01/2025 at a weighted average price of $23.6414, with sale prices ranging from $23.40 to $24.08. After the transactions the reporting person beneficially owned 13,126 shares. The filing notes the trades were made pursuant to a Rule 10b5-1 trading plan adopted on 12/11/2024, and the Form 4 was signed via attorney-in-fact on 10/03/2025.

Arthur A. Levin, Ph.D., a director of Stoke Therapeutics, reported equity awards and ownership changes on Form 4. On 09/30/2025 he became the beneficial owner of 1,211 restricted stock units (RSUs) that represent the right to receive one share each upon settlement. The filing shows these RSUs were recorded with a $0 price and are tied to settlement in common stock.

The report indicates 1,211 shares associated with the RSUs are held directly and that following the reported transaction the reporting person beneficially owned 3,631 shares directly and 17,979 shares indirectly through the Butler-Levin Revocable Trust, where he serves as trustee. The RSU award vests in quarterly 1/4 installments on the last day of March, June, September, and December, subject to continued service, with an indicated settlement date of 12/31/2025 for the reported tranche.

Stoke Therapeutics director Edward M. Kaye reported changes to his equity awards dated 09/04/2025. The filing shows an employee stock option covering 178,500 shares with an $8.33 exercise price was partially cancelled for no consideration under an exempt disposition, leaving 37,500 shares of common stock beneficially owned following the transaction. The option began vesting on April 15, 2025, and is scheduled to fully vest by December 15, 2026 if service continues. Separately, 144,000 restricted stock units were cancelled for no consideration; those RSUs had been scheduled to begin annual vesting on March 15, 2026. The report is filed on Form 4 and lists the reporting person as a director.

Stoke Therapeutics Chief Medical Officer Barry Ticho sold 5,501 shares of STOK common stock on 09/02/2025 under a Rule 10b5-1 trading plan adopted on 12/11/2024. The reported weighted-average sale price was $19.8737 per share, with individual trade prices ranging from $19.54 to $20.34 per share. After the reported sales, the reporting person beneficially owned 18,469 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Edward M. Kaye, MD, a director of Stoke Therapeutics (STOK), sold common stock in three transactions executed under a Rule 10b5-1 trading plan adopted December 30, 2024. The transactions show sales of 1,029 shares, 14,860 shares and 45,996 shares at weighted-average prices of $20.00 (single sale) and approximately $20.1386 and $20.1291 respectively. Following these reported sales the filing shows beneficial ownership of 91,585 shares, down from 152,441 shares after the first reported sale, reflecting a reduction of 60,856 shares in reported beneficial holdings. The filing discloses that the weighted-average sale prices ranged from $20.00 to $20.40 and that the reporting person will provide detailed per-price sale information on request.

Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics (STOK), reported multiple option exercises and open-market sales in late August and early September 2025. He exercised stock options at an exercise price of $7.07 on 08/29/2025 (850 shares) and 09/02/2025 (9,150 shares), and sold common stock in multiple transactions: 850 shares on 08/29/2025 at $20.00, 14,922 shares on 09/02/2025 at a weighted average $20.1375, and 6,345 shares on 09/03/2025 at a weighted average $20.0657. The filings state the sales were executed pursuant to a Rule 10b5-1 trading plan adopted 12/12/2024. After these transactions, the reporting person beneficially owned 11,831 shares of common stock and retained outstanding options covering additional shares.

Form 144 filed for STOK insider sale. The notice reports a proposed sale of 10,844 common shares with an aggregate market value of $214,277.44 to be executed through Morgan Stanley Smith Barney on NASDAQ on 09/02/2025. The filing identifies the shares as acquired via Restricted Stock Units (03/15/2025), Performance Stock Units (12/31/2024), and the Employee Stock Purchase Plan (06/30/2020), with respective amounts of 6,876, 1,483, and 2,485 shares.

The filing also lists recent dispositions by the same person, including sales on 08/18/2025 (2,805 shares), 08/01/2025 (4,504 shares), 07/01/2025 (4,503 shares), and 06/03/2025 (6,471 shares), several executed under a 10b5-1 plan. The filer affirms no undisclosed material adverse information and includes standard Rule 144 and 10b5-1 representations.